5AM Venture Management, LLC

In its 13F for Q1 2025 (holdings as of March 31, 2025, filed May 15, 2025), 5AM Venture Management, LLC reported 31 stock positions worth $264.4 million. Its top holding was Entrada Therapeutics (TRDA) at 15.1% of the portfolio, followed by Enliven Therapeutics (ELVN, 9.8%) and Dianthus Therapeutics (DNTH, 7.1%). Compared with Q4 2024, it opened 1 new position, sold out of 1 and reduced 2. The biggest buy was a new position in Surrozen (SRZN) and the biggest sale Tectonic Therapeutic (TECX, shares −14%).

Most Recent 13F
Q2 2026
Location
SAN FRANCISCO, CA
CIK
0001799883
Portfolio Value
$264.4M (Q1 2025)
SEC Filing
0001085146-25-003293 ↗ filed May 15, 2025

Holdings Value

0$100.0M$200.0M$300.0M$400.0M$500.0M Q1 2024: $446.6M Q1 2024 Q2 2024: $447.1M Q2 2024 Q3 2024: $484.0M Q3 2024 Q4 2024: $419.1M Q4 2024 Q1 2025: $264.4M $264.4M Q1 2025 Q2 2025: $260.1M Q2 2025 Q3 2025: $273.0M Q3 2025 Q4 2025: $318.1M Q4 2025 Q1 2026: $360.2M Q1 2026 Q2 2026: $287.9M Q2 2026

Holdings 31 stocks · $264.4M
TRDA Entrada Therapeutics Inc. 15.07% 4,408,379 $39.9M No change
ELVN Enliven Therapeutics Inc. 9.84% 1,322,477 $26.0M Reduce -18.9%
DNTH Dianthus Therapeutics Inc. 7.05% 1,027,711 $18.6M No change
SKYE Skye Bioscience Inc. 5.96% 9,913,168 $15.8M No change
PHVS Pharvaris NV 4.74% 797,600 $12.5M No change
CNTA Centessa Pharmaceuticals Ltd. 4.52% 830,945 $11.9M No change
CAMP CAMP4 Therapeutics Corp. 4.43% 2,927,915 $11.7M No change
BHVN Biohaven Ltd. 4.35% 478,972 $11.5M No change
MLTX Moonlake Immunotherapeutics 4.17% 282,313 $11.0M No change
VRDN Viridian Therapeutics Inc. 3.76% 736,595 $9.9M No change
TECX Tectonic Therapeutic Inc. 3.43% 511,660 $9.1M Reduce -14.3%
CLDX Celldex Therapeutics Inc. 3.41% 497,270 $9.0M No change
TYRA Tyra Biosciences Inc. 3.30% 939,298 $8.7M No change
ERAS Erasca Inc. 2.80% 5,405,404 $7.4M No change
ARTV Artiva Biotherapeutics Inc. 2.67% 2,353,304 $7.1M No change
ANAB Anaptysbio Inc. 2.52% 357,733 $6.7M No change
PRAX Praxis Precision Medicines I 2.43% 170,000 $6.4M No change
GHRS GH Research PLC 2.39% 572,665 $6.3M No change
EYPT Eyepoint Inc. 2.15% 1,050,000 $5.7M No change
VKTX Viking Therapeutics Inc. 1.73% 189,593 $4.6M No change
VOR Vor Biopharma Inc. 1.73% 6,361,723 $4.6M No change
SRZN Surrozen Inc. 1.37% 310,000 $3.6M New
TARA Protara Therapeutic Inc. 1.29% 800,000 $3.4M No change
SCPH Scpharmaceuticals Inc. 1.19% 1,200,647 $3.2M No change
RLYB Rallybio Corp. 0.90% 3,630,724 $2.4M No change
ADVM Adverum Biotechnologies Inc. 0.90% 541,666 $2.4M No change
SLN Silence Therapeutics PLC-ADR 0.51% 476,200 $1.3M No change
ALEC Alector Inc. 0.46% 995,841 $1.2M No change
CDTX Cidara Therapeutics Inc. 0.46% 56,725 $1.2M No change
ZNTL Zentalis Pharmaceuticals Inc. 0.29% 490,000 $779K No change
MERSANA THERAPEUTICS INC 0.17% 1,305,000 $449K No change

Portfolio Sells Q4 2024 → Q1 2025
TECX Tectonic Therapeutic Inc. Reduce -14.3% 3.43% −3.15
AKRO Akero Therapeutics Inc. Sold out 0.00% −1.10
ELVN Enliven Therapeutics Inc. Reduce -18.9% 9.84% +1.09

Portfolio Buys Q4 2024 → Q1 2025
SRZN Surrozen Inc. New 1.37% +1.37

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 16$287.9MMPLT, TYRA, TRDA, PHVS, CAMP
Q1 2026 20$360.2MERAS, TRDA, TYRA, CAMP, CNTA
Q4 2025 21$318.1MTRDA, CAMP, TYRA, VRDN, PHVS
Q3 2025 25$273.0MSKYE, TRDA, PHVS, CAMP, CNTA
Q2 2025 29$260.1MSKYE, TRDA, DNTH, ELVN, PHVS
Q1 2025 31$264.4MTRDA, ELVN, DNTH, SKYE, PHVS
Q4 2024 31$419.1MTRDA, ELVN, SKYE, TECX, ARTV
Q3 2024 28$484.0MTRDA, ELVN, SKYE, ARTV, DNTH
Q2 2024 28$447.1MSKYE, TRDA, ELVN, DNTH, CLDX
Q1 2024 26$446.6MELVN, TRDA, DNTH, MRUS, CLDX